NASDAQ:STRO Sutro Biopharma Q3 2025 Earnings Report $15.98 +0.27 (+1.72%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$15.92 -0.07 (-0.41%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sutro Biopharma EPS ResultsActual EPS-$0.67Consensus EPS -$0.42Beat/MissMissed by -$0.25One Year Ago EPSN/ASutro Biopharma Revenue ResultsActual Revenue$9.69 millionExpected Revenue$10.14 millionBeat/MissMissed by -$451.00 thousandYoY Revenue GrowthN/ASutro Biopharma Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time4:00PM ETUpcoming EarningsSutro Biopharma's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Sutro Biopharma Earnings HeadlinesSutro Biopharma (NASDAQ:STRO) Downgraded by Wall Street Zen to Strong SellSeptember 19, 2026 | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)August 14, 2026 | theglobeandmail.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)STRO stock plummets 15% — what drove the selloff?August 12, 2026 | msn.comWhy is Sutro Biopharma Stock Falling On Wednesday?August 12, 2026 | benzinga.comSutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 StudyAugust 12, 2026 | globenewswire.comSee More Sutro Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sutro Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sutro Biopharma and other key companies, straight to your email. Email Address About Sutro BiopharmaSutro Biopharma (NASDAQ:STRO) is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company uses its proprietary XpressCF cell-free protein synthesis platform to design and manufacture antibody-drug conjugates (ADCs) and immunostimulatory antibody conjugates intended to selectively target tumor cells while limiting damage to healthy tissue. Sutro’s pipeline has included luveltamab tazevibulin, also known as luvelta or STRO-002, a folate receptor alpha-directed ADC being investigated for the treatment of ovarian and endometrial cancers. The company has also advanced additional preclinical and clinical programs directed at cancer-related targets, including therapies designed to deliver cytotoxic or immune-activating payloads to tumors. Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma conducts research and development activities in the United States and works with external pharmaceutical partners on selected programs. The company’s operations are primarily focused on oncology research, drug discovery, clinical development and manufacturing-related capabilities. Sutro is led by a management team with experience in biotechnology, pharmaceutical development and oncology therapeutics.View Sutro Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
